UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The characterization of social anhedonia and its correlates in schizophrenia and schizoaffective patients

Psychiatry research, 2018-12, Vol.270, p.922-928

2018

Volltextzugriff (PDF)

Predicting Predischarge Anhedonia Among Inpatients With Schizophrenia and Schizoaffective Disorders: A Large-scale Analysis

The journal of nervous and mental disease, 2019-01, Vol.207 (1), p.12-21

2019

Volltextzugriff (PDF)

Pregnenolone treatment reduces severity of negative symptoms in recent‐onset schizophrenia: An 8‐week, double‐blind, randomized add‐on two‐center trial

Psychiatry and clinical neurosciences, 2014-06, Vol.68 (6), p.432-440

2014

Volltextzugriff (PDF)

Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial

The journal of clinical psychiatry, 2010-10, Vol.71 (10), p.1351-1362

2010

Volltextzugriff (PDF)

Patients' satisfaction with hospital health care: Identifying indicators for people with severe mental disorder

Psychiatry research, 2018-12, Vol.270, p.503-509

2018

Volltextzugriff (PDF)

Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors

Quality of life research, 2012-06, Vol.21 (5), p.837-847

2012

Volltextzugriff (PDF)

Anhedonia Is an Important Factor of Health-Related Quality-of-Life Deficit in Schizophrenia and Schizoaffective Disorder

The journal of nervous and mental disease, 2011-11, Vol.199 (11), p.845-853

2011

Volltextzugriff (PDF)

The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial

The journal of clinical psychiatry, 2013-12, Vol.74 (12), p.1224-1232

2013

Volltextzugriff (PDF)

Assessment of health needs, satisfaction with care, and quality of life in compulsorily admitted patients with severe mental disorders

Psychiatry research, 2018-09, Vol.267, p.541-550

2018

Volltextzugriff (PDF)

Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors

Quality of life research, 2012-08, Vol.21 (6), p.1075-1084

2012

Volltextzugriff (PDF)

Predicting Quality of Life Impairment in Chronic Schizophrenia from Cognitive Variables

Quality of life research, 2007-08, Vol.16 (6), p.929-937

Ritsner, Michael S.

2007

Volltextzugriff (PDF)

Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials

CNS neuroscience & therapeutics, 2010-02, Vol.16 (1), p.32-44

Ritsner, Michael S.

2010

Volltextzugriff (PDF)

Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Clinical schizophrenia & related psychoses, 2017, Vol.10 (4), p.201-210

2017

Volltextzugriff (PDF)

L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study

The journal of clinical psychiatry, 2011-01, Vol.72 (1), p.34-42

2011

Volltextzugriff (PDF)

Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Clinical schizophrenia & related psychoses, 2018-03, Vol.12 (1), p.31-41

2018

Volltextzugriff (PDF)

Anhedonia of Patients with Schizophrenia and Schizoaffective Disorder is Attributed to Personality-Related Factors Rather than to State-Dependent Clinical Symptoms

Clinical schizophrenia & related psychoses, 2016, Vol.9 (4), p.187-197C

Ritsner, Michael S

2016

Volltextzugriff (PDF)

Predicting 10‐year quality‐of‐life outcomes of patients with schizophrenia and schizoaffective disorders

Psychiatry and clinical neurosciences, 2014-04, Vol.68 (4), p.308-317

2014

Volltextzugriff (PDF)

Validity of an Abbreviated Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-18) for Schizophrenia, Schizoaffective, and Mood Disorder Patients

Quality of life research, 2005-09, Vol.14 (7), p.1693-1703

2005

Volltextzugriff (PDF)

Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date

CNS drugs, 2016-04, Vol.30 (4), p.269-280

2016

Volltextzugriff (PDF)

Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits

Psychiatry research, 2007-01, Vol.149 (1), p.59-69

2007

Volltextzugriff (PDF)

Symptom severity scale of the DSM5 for schizophrenia, and other psychotic disorders: diagnostic validity and clinical feasibility

Psychiatry research, 2013-06, Vol.208 (1), p.1-8

2013

Volltextzugriff (PDF)

Factor structure in the Camberwell Assessment of Need-Patient Version: The correlations with dimensions of illness, personality and quality of life of schizophrenia patients

Psychiatry and clinical neurosciences, 2012-10, Vol.66 (6), p.499-507

2012

Volltextzugriff (PDF)

Ten-Year Quality-of-Life Outcomes of Patients with Schizophrenia and Schizoaffective Disorders: The Relationship with Unmet Needs for Care

Clinical schizophrenia & related psychoses, 2015-09, Vol.9 (3), p.125-134A

2015

Volltextzugriff (PDF)

Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: A multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA

Journal of psychiatric research, 2010-01, Vol.44 (2), p.75-80

2010

Volltextzugriff (PDF)

Determinants of Changes in Perceived Quality of Life in the Course of Schizophrenia

Quality of life research, 2006-04, Vol.15 (3), p.515-526

2006

Volltextzugriff (PDF)

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(126)

Publikationsform

Artikel
(103)
Buchkapitel
(45)
Bücher
(3)

Sprache

Englisch
(151)

Erscheinungsjahr

n.n

Thema

Humans
(88)
Life Sciences & Biomedicine
(88)
Science & Technology
(88)
Male
(80)
Adult
(79)
Female
(77)
Psychiatry
(77)
Schizophrenia
(73)
Middle Aged
(69)
Biological And Medical Sciences
(57)
Medical Sciences
(56)
Psychology. Psychoanalysis. Psychiatry
(56)
Psychopathology. Psychiatry
(54)
Adult And Adolescent Clinical Studies
(48)
Psychoses
(38)
Schizophrenic Psychology
(37)
Quality Of Life
(34)
Adolescent
(31)
Neurosciences & Neurology
(28)
Schizophrenia - Drug Therapy
(25)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The characterization of social anhedonia and its correlates in schizophrenia and schizoaffective patients

Predicting Predischarge Anhedonia Among Inpatients With Schizophrenia and Schizoaffective Disorders: A Large-scale Analysis

Pregnenolone treatment reduces severity of negative symptoms in recent‐onset schizophrenia: An 8‐week, double‐blind, randomized add‐on two‐center trial

Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial

Patients' satisfaction with hospital health care: Identifying indicators for people with severe mental disorder

Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors

Anhedonia Is an Important Factor of Health-Related Quality-of-Life Deficit in Schizophrenia and Schizoaffective Disorder

The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial

Assessment of health needs, satisfaction with care, and quality of life in compulsorily admitted patients with severe mental disorders

Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors

Predicting Quality of Life Impairment in Chronic Schizophrenia from Cognitive Variables

Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials

Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial

L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study

Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Anhedonia of Patients with Schizophrenia and Schizoaffective Disorder is Attributed to Personality-Related Factors Rather than to State-Dependent Clinical Symptoms

Predicting 10‐year quality‐of‐life outcomes of patients with schizophrenia and schizoaffective disorders

Validity of an Abbreviated Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-18) for Schizophrenia, Schizoaffective, and Mood Disorder Patients

Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date

Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits

Symptom severity scale of the DSM5 for schizophrenia, and other psychotic disorders: diagnostic validity and clinical feasibility

Factor structure in the Camberwell Assessment of Need-Patient Version: The correlations with dimensions of illness, personality and quality of life of schizophrenia patients

Ten-Year Quality-of-Life Outcomes of Patients with Schizophrenia and Schizoaffective Disorders: The Relationship with Unmet Needs for Care

Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: A multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA

Determinants of Changes in Perceived Quality of Life in the Course of Schizophrenia

Suchergebnisse filtern